Innovent Biologics

Join us for our upcoming semi-annual results conference call! We'll be sharing exciting updates on our pipeline progress, key milestones and overall achievements. Don't miss this opportunity to hear directly from our leadership team. Registration details below.

Celebrating 13 Years of Innovation at Innovent! What a journey it's been! Over the past 13 years, we've brought 11 groundbreaking therapies to market, advancing the fields of oncology, immunology, cardiovascular and metabolism (CVM), and ophthalmology. This success wouldn't have been possible without our incredible teams, dedicated partners, supportive community, and of course, the patients who inspire us every day. Together, we're pushing the boundaries of science and creating a brighter, healthier future for all. Here's to many more years of discovery and impact! #InnoventBiologics #Teamwork

We're proud to announce that Dupert® (fulzerasib) has been approved as China's first KRAS G12C inhibitor for advanced NSCLC patients with the KRAS G12C mutation who have undergone prior systemic therapy! NSCLC makes up roughly 85% of lung cancer cases, with KRAS mutations detected in 15-20% of them. This approval marks Dupert® as Innovent's eleventh product in our portfolio, advancing our mission to deliver affordable, high-quality biopharmaceuticals to patients worldwide. https://lnkd.in/gHHddp_z #InnoventBiologics #HealthCare

We are thrilled to announce that Innovent and Sanegene Bio have successfully dosed the first participant in a Phase 1 first-in-human clinical trial of IBI3016 (SGB-3908), an siRNA drug candidate targeting angiotensinogen (AGT) for hypertension treatment. Hypertension, affecting over 1 billion people globally, poses serious health risks including cardiovascular diseases, kidney damage, and impaired vision. As global hypertension rates rise, IBI3016 promises a groundbreaking solution for better health outcomes. https://lnkd.in/gs8gPgaj #InnoventBiologics #HealthCare

We are excited to announce that the NDA for mazdutide has been accepted by China's NMPA for the treatment of type 2 diabetes! As the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials for T2D, mazdutide promises to offer a new treatment option with comprehensive advantages in glycemic control, weight reduction, and wide-ranging metabolic benefits. https://lnkd.in/gPec_3XE #InnoventBiologics #Mazdutide

On World Hepatitis Day 2024, we support accelerating efforts in diagnosing, treating and preventing hepatitis. In China, hepatitis B and C viruses are major causes of liver cancer, creating a significant health burden. Many cases are still undiagnosed, highlighting the urgent need for better testing and treatment. At Innovent, we have several products regulatorily approved for the treatment of liver cancers and are currently conducting clinical studies on other assets to improve liver cancer treatments. We are committed to making a positive impact on the lives of those affected.#WorldHepatitisDay #TimeforAction #InnoventBiologics

We're excited to announce a new partnership with WeComput to enhance Innovent Academy's Computing Platform for faster, AI-driven drug discovery. We're using WeComput's WeMol platform to upgrade our R&D capabilities with advanced molecular design, along with NVIDIA's #BioNeMo to boost computing for developing new healthcare solutions. https://lnkd.in/gsCxtj7c #InnoventBiologics #HealthCare

We are proud to announce that DREAMS-1, our Phase 3 clinical trial of mazdutide in Chinese adults with type 2 diabetes (T2D) met primary and key secondary endpoints! With DREAMS-2 for the treatment of T2D also achieving its study goals, we’re preparing to submit another NDA for mazdutide to China’s NMPA, marking a significant step in advancing diabetes treatment. #InnoventBiologics #Mazdutide https://lnkd.in/geJcm_ci

Our new ESG website is live! At Innovent, our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals drives us to integrate ESG principles into every aspect of our value chain. We are dedicated to ensuring the highest quality in our products, while also caring for our people and the environment. Discover more about our commitment to Environmental, Social and Governance (ESG) initiatives on our newly launched website: https://lnkd.in/gzQrv-gW #ESG #Sustainability #Healthcare #InnoventBiologics

We are thrilled to announce that Innovent has been recognized in Universum's "2024 China's Most Attractive Employers Rankings"! 🏅 10th Position as the Most Attractive Employer for natural science students 🏅 19th Position as the Most Attractive Employer for health/medicine students 🏅 Top 100 Most Attractive Employers for engineering students This achievement highlights our commitment to innovation, mentorship, excellence in cutting-edge research and therapies, strong corporate social responsibility and our inspiring mission and vision. We're grateful to our incredible team and community for making this possible. Together, we are creating a supportive workplace, prioritizing employee wellness, and inspiring our team to make a positive difference in healthcare. #InnoventBiologics #Healthcare #Universum2024